Researchers at the German Center for Infection Research (DZIF) at Heidelberg University Hospital have decoded a previously unknown mechanism by which ...

A partnership will enable low-cost, generic lenacapavir for HIV prevention in LMICs, aiming to improve access and reduce ...

Gilead offers a meaningful upside opportunity should it execute on increasing revenue growth to the low-to-middle single ...

Penobscot County, Maine, is grappling with the largest HIV outbreak in the state's history. Home to Bangor, a city of roughly ...

The 39th annual event aims to raise $500,000 to support Whitman-Walker’s HIV testing, outreach, prevention, and treatment ...

A multi-institutional team led by Weill Cornell Medicine investigators has been awarded a five-year, $20.8 million grant from ...

New partnership will join others to expand access to generic lenacapavir for millions more people at risk of HIV in high-burden countries—bringing the world closer to ending the epidemic - Kenya ...

Lupin Ltd has gained tentative approval from the US FDA for its generic version of an HIV drug, set to be manufactured at its Nagpur facility.

The announcement comes at a troubling time for global health, particularly in the fight against HIV/AIDS, as US foreign aid ...

Generics of Gilead Sciences' twice-yearly HIV pre-exposure prophylaxis (PrEP) Yeztugo (lenacapavir) are on the horizon, with ...